Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure

Medical Science Monitor

Volumn 18, Issue 1, 2012, Pages

  Celik, Atac ^a   Sahin, Semsettin ^a   Koc, Fatih ^a   Karayakali, Metin ^a   Sahin, Mehmet ^a   Benli, Ismail ^a   Kadi, Hasan ^a   Burucu, Turgay ^a   Ceyhan, Koksal ^a   Erkorkmaz, Unal ^a  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

Cardiotrophin 1; Diastolic heart failure; N terminal pro B type natriuretic peptide; Tissue doppler echocardiography

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARDIOTROPHIN 1;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; BLOOD SAMPLING; CONTROLLED STUDY; DIASTOLIC HEART FAILURE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE FILLING; HEART OUTPUT MEASUREMENT; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; PROTEIN BLOOD LEVEL; PULMONARY ARTERY OCCLUSION PRESSURE;

EID: 84855280828     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.882197     Document Type: Article

References (36)

1. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation, 2002; 105: 1387-93
2. Hogg K, Swedberg K, McMurray J: Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol, 2004; 43: 317-27
3. El-Waseef MM, Taha S, Elgindi H: Left ventricular diastolic abnormal ities and the impact of hepatitis C virus infection in multitransfused Egyptian children. Arch Med Sci, 2010; 6(1): 96-99
4. Chatterjee K, Massie B: Systolic and diastolic heart failure: differences and similarities. J Card Fail, 2007; 13: 569-56
5. Stejskal D, Ruzicka V: Cardiotrophin-1. Review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2008; 152: 9-19
6. Jougasaki M: Cardiotrophin-1 in cardiovascular regulation. Adv Clin Chem, 2010; 52: 41-76
7. Pennica D, Wood WI, Chien KR: Cardiotrophin-1: a multifunctional cytokine that signals via LIF receptor-gp 130 dependent pathways. Cytokine Growth Factor Rev, 1996; 7: 81-91
8. Talwar S, Squire IB, Downie PF et al: Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci (Lond), 2000; 99: 83-88
9. Tsutamoto T, Asai S, Tanaka T et al: Plasma level of cardiotrophin-1 as a prognostic predictor in patients with chronic heart failure. Eur J Heart Fail, 2007; 9: 1032-37
10. Gonzalez A, Lopez B, Martin-Raymondi D et al: Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens, 2005; 23: 2297-304
11. Lopez B, Castellano JM, Gonzalez A et al: Association of increased plasma cardiotrophin-1 with inappropriate left ventricular mass in essential hypertension. Hypertension, 2007; 50: 977-83
12. Talwar S, Squire IB, Davies JE, Ng LL: The effect of valvular regurgitation on plasma Cardiotrophin-1 in patients with normal left ventricular systolic function. Eur J Heart Fail, 2000; 2: 387-91
13. Talwar S, Downie PF, Squire IB et al: Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Eur J Heart Fail, 2001; 3: 15-19
14. Talwar S, Squire IB, Downie PF et al: Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart, 2000; 84: 421-24
15. Khan SQ, Kelly D, Quinn P et al: Cardiotrophin-1 predicts death or heart failure following acute myocardial infarction. J Card Fail, 2006; 12: 635-40
16. Talwar S, Squire IB, O'brien RJ et al: Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction. Clin Sci (Lond), 2002; 102: 9-14
17. Tsutamoto T, Wada A, Maeda K et al: Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy. J Am Coll Cardiol, 2001; 38: 1485-90
18. Monserrat L, López B, González A et al: Cardiotrophin-1 plasma levels are associated with the severity of hypertrophy in hypertrophic cardiomyopathy. Eur Heart J, 2011; 32: 177-83
19. Dickstein K, Cohen-Solal A, Filippatos G et al: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail, 2008; 10: 933-89
20. Devereux RB, Alonso DR, Lutas EM et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol, 1986; 57: 450-58
21. Nagueh SF, Middleton KJ, Kopelen HA et al: Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol, 1997; 30: 1527-33
22. Nagueh SF, Appleton CP, Gillebert TC et al: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr, 2009; 22: 107-33
23. Kuwahara K, Saito Y, Harada M et al: Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation, 1999; 100: 1116-24
24. Sano M, Fukuda K, Kodama H et al: Autocrine/Paracrine secretion of Interleukin-6 family of cytokines causes angiotensin II-induced delayed STAT3 activation. Biochem Biophys Res Commun, 2000; 269: 798-802
25. Funamoto M, Hishinuma S, Fujio Y et al: Isolation and characterization of the murine cardiotrophin-1 gene: expression and norepinephrine-induced transcriptional activation. J Mol Cell Cardiol, 2000; 32: 1275-84
26. Pemberton CJ, Raudsepp SD, Yandle TG et al: Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc Res, 2005; 68: 109-17
27. Calabro P, Limongelli G, Riegler L et al: Novel insights into the role of cardiotrophin-1 in cardiovascular diseases. J Mol Cell Cardiol, 2009; 46: 142-48
28. Jin H, Yang R, Ko A et al: Effects of cardiotrophin-1 on haemodynamics and cardiac function in conscious rats. Cytokine, 1998; 10: 19-25
29. Ng LL, O'Brien RJ, Demme B, Jennings S: Non-competitive immunochemiluminometric assay for cardiotrophin-1 detects elevated plasma levels in human heart failure. Clin Sci (Lond), 2002; 102: 411-16
30. Jougasaki M, Tachibana I, Luchner A et al: Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation, 2000; 101: 14-17
31. López B, González A, Lasarte JJ et al: Is plasma cardiotrophin-1 a marker of hypertensive heart disease? J Hypertens, 2005; 23: 625-32
32. Dahlström U: Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur J Heart Fail, 2004; 6: 281-87
33. Tuǧcu A, Yildirimtürk O, Aytekin S: The diagnostic value of N-terminal B-type natriuretic peptide in diastolic heart failure: comparison with echocardiographic findings. Turk Kardiyol Dern Ars, 2009; 37: 112-21
34. Krzych LJ, Liszka L: No improvement in studies reporting the diagnostic accuracy of B-type natriuretic peptide. Med Sci Monit, 2009; 15(5): SR5-14
35. Zvonic S, Hogan JC, Arbour-Reily P et al: Effects of cardiotrophin on adipocytes. J Biol Chem, 2004; 279: 47572-79
36. Natal C, Fortuńo MA, Restituto P et al: Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome. Am J Physiol Endocrinol Metab, 2008; 294: E52-60